Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

350 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
Bailly F, Virlogeux V, Dufour C, Pradat P, Hézode C, Larrey D, Alric L, Samuel D, Bourlière M, Métivier S, Zarski JP, Fontaine H, Loustaud-Ratti V, Serfaty L, Bronowicki JP, Carrat F, Zoulim F; CUPIC Study Group. Bailly F, et al. Among authors: alric l. Clin Res Hepatol Gastroenterol. 2015 Sep;39(4):443-50. doi: 10.1016/j.clinre.2014.12.007. Epub 2015 Jan 27. Clin Res Hepatol Gastroenterol. 2015. PMID: 25636238
Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort.
Morin T, Pariente A, Lahmek P, Rabaud C, Silvain C, Cadranel JF; Association Nationale des Hépato-gastroentérologues des Hôpitaux généraux (ANGH) Société de Pathologie Infectieuse de Langue Française (SPILF) Fédération des Pôles de Référence et Réseaux Hépatites (FPRRH). Morin T, et al. Eur J Gastroenterol Hepatol. 2010 Feb;22(2):157-66. doi: 10.1097/MEG.0b013e328330a8e8. Eur J Gastroenterol Hepatol. 2010. PMID: 19734798
Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy.
Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, Lunel-Fabiani F, Bouviers-Alias M, Trimoulet P, Chaix ML, Hézode C, Foucher J, Fontaine H, Roque-Afonso AM, Gassin M, Schvoerer E, Gaudy C, Roche B, Doffoël M, D'Alteroche L, Vallet S, Baazia Y, Pozzetto B, Thibault V, Nousbaum JB, Roulot D, Coppere H, Poynard T, Payan C, Izopet J. Legrand-Abravanel F, et al. Among authors: alric l. J Med Virol. 2009 Dec;81(12):2029-35. doi: 10.1002/jmv.21583. J Med Virol. 2009. PMID: 19856464 Free article.
Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease.
Peck-Radosavljevic M, Boletis J, Besisik F, Ferraz ML, Alric L, Samuel D, Messinger D, Tietz A, Cheinquer H. Peck-Radosavljevic M, et al. Among authors: alric l. Clin Gastroenterol Hepatol. 2011 Mar;9(3):242-8. doi: 10.1016/j.cgh.2010.10.018. Epub 2010 Nov 5. Clin Gastroenterol Hepatol. 2011. PMID: 21056689 Clinical Trial.
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).
Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM. Chevaliez S, et al. Among authors: alric l. Gastroenterology. 2011 Jul;141(1):119-27. doi: 10.1053/j.gastro.2011.03.039. Epub 2011 Mar 24. Gastroenterology. 2011. PMID: 21439960 Free article. Clinical Trial.
Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir).
Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, Chaffaut C, Chevret S, Trinchet JC, Salmon D; ANRS CO13 Hepavih study group; ANRS CO12 Cirvir study group. Bourcier V, et al. Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):214-21. doi: 10.1016/j.clinre.2011.11.002. Epub 2011 Dec 19. Clin Res Hepatol Gastroenterol. 2012. PMID: 22189509 Free article.
Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
Loko MA, Bani-Sadr F, Valantin MA, Lascoux-Combe C, Fontaine H, Bonnard P, Gervais A, Bouchaud O, Garipuy D, Quertainmont Y, Vittecoq D, Tehrani MS, Winnock M, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group. Loko MA, et al. Antivir Ther. 2012;17(7):1335-43. doi: 10.3851/IMP2419. Epub 2012 Oct 10. Antivir Ther. 2012. PMID: 23052829
Hepatitis C virus and kidney disease.
Kamar N, Alric L, Izopet J, Rostaing L. Kamar N, et al. Among authors: alric l. Clin Res Hepatol Gastroenterol. 2013 Sep;37(4):328-33. doi: 10.1016/j.clinre.2013.02.010. Epub 2013 Mar 21. Clin Res Hepatol Gastroenterol. 2013. PMID: 23522570 Review.
350 results